亚洲知识产权资讯网为知识产权业界提供一个一站式网上交易平台，协助业界发掘知识产权贸易商机，并与环球知识产权业界建立联系。无论你是知识产权拥有者正在出售您的知识产权，或是制造商需要购买技术以提高操作效能，又或是知识产权配套服务供应商，你将会从本网站发掘到有用的知识产权贸易资讯。

返回搜索结果

Preconditioned Human Mesenchymal Stem Cells (hMSCs) for Musculoskeletal Tissue Repair

技术优势: Improved cell survival and engraftment Able to manipulate biophysical properties of spheroid-hydrogel system

详细技术说明: Bone defects that extend beyond a critical size are associated with impaired native healing due to age or disease. Approximately 10% of patients with bone defects do not have sufficient bone repair processes, leading to fractures, infections, and other comorbidities. Human mesenchymal stem cell (hMSC)-based therapies have high therapeutic potential for such bone repair but have limited efficacy in vivo: calcification of surrounding tissue occurs due to limited oxygen supply and decreased nutrient exchange. Researchers at the University of California, Davis have developed a novel treatment for bone repair that offers an optimized survival rate of human mesenchymal stem cells and engraftment once implanted into a bone defect. The method incorporates pre-treatment of the cells combined with an engineered cell carrier system, resulting in synergistically improved bone healing compared to existing monolayer cell therapies and spheroid formation methods. This method has successfully exhibited higher cell density, osteogenic potential and increased secretion of proangiogenic factors in vitro with significantly more bone healing in critical-sized femoral segment defects in rats in vivo. This method represents a simple approach for enhanced, long-term therapeutic bone healing.

*Abstract: Researchers at the University of California, Davis have developed a preconditioning treatment and delivery method for human mesenchymal stem cell (hMSC) for enhanced bone healing.

*Principal Investigation: Name: Steve Ho
Department:

Name: Kent Leach
Department:

欲了解更多信息，请点击这里